HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice - Episode 7

Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

, , , ,

Experts on breast cancer discuss the potential impact of ongoing research in HER2+ breast cancer, highlighting how results from the DESTINY-Breast07 study may translate to DESTINY-Breast09.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Challenges in Diagnosing HER2+ Breast Cancer
    EP. 2: Neoadjuvant Treatment Options in HER2+ Early Breast Cancer
    EP. 3: Preoperative Monitoring and Surgical Options for HER2+ Patients
    EP. 4: Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer
    EP. 5: Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC
    EP. 6: Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer
    Now Viewing
    EP. 7: Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets
    EP. 8: Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges
    EP. 9: Overview of DESTINY-Breast06
    EP. 10: Clinical Perspectives on Managing ILD Related to T-DXd
    EP. 11: Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC
    EP. 12: Unmet Needs and Future Direction in HER2+ Breast Cancer

    Video content above is prompted by the following questions:

    • How would the results of the DESTINY-Breast09 trial impact your clinical practice?
    • What are your thoughts on the other trials mentioned above if they do result in positive results in PFS? How would they be applied to your treatment of different patient subsets?
    x